Recent News

• 05.14.2025 - Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
• 05.14.2025 - Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
• 03.31.2025 - Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
• 03.11.2025 - Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
• 02.05.2025 - Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
• 02.05.2025 - Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Recent Filings

• 04.22.2025 - DEF 14A Other definitive proxy statements
• 04.22.2025 - ARS Annual Report to Security Holders
• 04.22.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.25.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 8-K Current report